Nirmatrelvir

Definition

An orally bioavailable, peptidomimetic inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro; 3C-like protease; 3CL protease; 3CLpro; nsp5 protease), with potential antiviral activity against SARS-CoV-2 and other coronaviruses. Upon oral administration, nirmatrelvir selectively targets, binds to, and inhibits the activity of SARS-CoV-2 Mpro. This inhibits the proteolytic cleavage of viral polyproteins, thereby inhibiting the formation of viral proteins including helicase, single-stranded-RNA-binding protein, RNA-dependent RNA polymerase, 20-O-ribose methyltransferase, endoribonuclease and exoribonuclease. This prevents viral transcription and replication.

Also known as NIRMATRELVIR, PF 07321332, PF-07321332, PF07321332, SARS-CoV-2 3CLpro Inhibitor PF-07321332, SARS-CoV-2-3CL Protease Inhibitor PF-07321332 — per NCIT

Also identified as

• NCIT NCIT:C182119 per NCIT
• SCTID 1332141006 per RXNORM
• SCTID 1332459000 per RXNORM
• UNII 7R9A5P7H32 per RXNORM

Indications